Hearing loss after platinum chemotherapy in people with cancer from different backgrounds
Looks at hearing changes after platinum chemotherapy in adults with cancer.
Key facts
- Who runs it
- Lancaster University
- Where
- United Kingdom1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Chemotherapy-Induced Hearing Loss and Health Inequality
- Status
- Recruiting
- People taking part
- 172 people, planned
- Started
- 2 May 2026
- Expected to end
- 1 Sept 2028
- Type of study
- Observational
- Record updated
- 10 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with cancer who are getting platinum-based chemotherapy, such as cisplatin, in North West England. It studies hearing loss and thinking skills.
- Age
- 18 Years and older
- Sex
- All
- Disease stage
- Stage 4 cancer cannot join. People with a WHO performance status score of 3 or more cannot join. This score measures how well you manage daily activities.
- Earlier treatment
- People must be receiving platinum-based chemotherapy drugs.
Main reasons for not taking part
- Brain tumour or cancer spread to the brain, head and neck cancer, skin cancer around the ear, or adenoid cystic carcinoma of the auditory cortex
- Deafness in childhood, a cochlear implant, or current or recent ear infections
- Known nerve or brain problems, such as stroke, brain injury or dementia
- Not able to give consent or do the study tasks
- Must live and be treated in North West England, speak English fluently, and be able to do an online hearing and thinking test
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Patients receiving platinum-based chemotherapy drugs
- Living and treated within North West England
- Able to complete an online hearing and cognitive test
- Fluent in English
Who cannot take part
- Cochlear implant user
- Following cancer types: brain tumour/metastasis, head + neck, skin cancers around the ear, and adenoid cystic carcinoma of the auditory cortex
- Stage 4 cancer
- History of childhood deafness
- Current or recent ear infections
- Known neurological impairment (e.g., stroke, traumatic brain injury, dementia)
- World Health Organisation performance status score of 3 or more
- Patients who look capacity to consent or complete study tasks
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This project aims to understand how platinum-based chemotherapy affects hearing function in cancer patients from different socioeconomic backgrounds in the North West of England. Platinum-based chemotherapy drugs, such as cisplatin, are ototoxic, meaning that they cause permanent damage to the hair cells of the ear, resulting in hearing loss. Patients from more deprived backgrounds face additional risk factors to their hearing health, including limited healthcare access, greater occupational noise exposure, and poorer overall health, making them more vulnerable to hearing loss.
Read full original descriptionShow less
This is especially concerning as hearing loss can make communication more challenging, which creates a greater reliance on cognitive processes such as thinking and memory to navigate social interactions. This challenge is exacerbated when individuals experience cognitive dysfunction related to chemotherapy, commonly referred to as 'chemo brain'. Addressing these communication difficulties is crucial for promoting healthy ageing and maintaining social engagement. It is expected that cancer patients from the most deprived backgrounds would experience greater hearing loss following chemotherapy than those from less deprived backgrounds.
As a secondary aim, this study will also investigate how hearing loss may affect cognitive function. Specifically, it will assess whether differences in speech-in-noise performance from pre- to post-treatment predict cognitive performance post-treatment, to understand if changes in hearing over time are associated with changes in cognition. The study will also explore how socioeconomic deprivation, cumulative chemotherapy dose, and treatment duration influence these relationships. By identifying disparities in hearing loss and possible associations with cognition, this research will help guide future hearing screening and intervention strategies for cancer patients.
The group in the trial
- Chemotherapy patients
Patients set to be treated with platinum-based chemotherapy drugs in the North West of England.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Chemotherapy-Induced Hearing Loss and Health Inequality
- Plain-language title
- Hearing loss after platinum chemotherapy in people with cancer from different backgroundsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 10 September 2026